

DPYD gene

dihydropyrimidine dehydrogenase

Normal Function

The *DPYD* gene provides instructions for making an enzyme called dihydropyrimidine dehydrogenase, which is involved in the breakdown of molecules called uracil and thymine when they are not needed. Uracil and thymine are pyrimidines, which are one type of nucleotide. Nucleotides are building blocks of DNA, its chemical cousin RNA, and molecules such as ATP and GTP that serve as energy sources in the cell.

Dihydropyrimidine dehydrogenase is involved in the first step of the breakdown of pyrimidines. This enzyme converts uracil to another molecule called 5,6-dihydrouracil and converts thymine to 5,6-dihydrothymine. The molecules created when pyrimidines are broken down are excreted by the body or used in other cellular processes.

Health Conditions Related to Genetic Changes

Dihydropyrimidine dehydrogenase deficiency

More than 50 mutations in the *DPYD* gene have been identified in people with dihydropyrimidine dehydrogenase deficiency. *DPYD* gene mutations interfere with the breakdown of uracil and thymine and result in excess quantities of these molecules in the blood, urine, and the fluid that surrounds the brain and spinal cord (cerebrospinal fluid). It is unclear how the excess uracil and thymine are related to the specific neurological problems that affect some people with dihydropyrimidine dehydrogenase deficiency.

Mutations in the *DPYD* gene also interfere with the breakdown of drugs with structures similar to the pyrimidines, such as the cancer drugs 5-fluorouracil and capecitabine. As a result, these drugs accumulate in the body and cause the severe reactions that can occur in people with dihydropyrimidine dehydrogenase deficiency.

Coloboma

MedlinePlus Genetics provides information about Coloboma

Other Names for This Gene

- DHP
- DHPDHASE
- dihydropyrimidine dehydrogenase [NADP+]
- dihydrothymine dehydrogenase
- dihydrouracil dehydrogenase
- DPD
- DPYD_HUMAN
- MGC132008
- MGC70799

Additional Information & Resources

Tests Listed in the Genetic Testing Registry

- Tests of DPYD ([https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=1806\[geneid\]](https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=1806[geneid]))

Scientific Articles on PubMed

- PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=%28%28DPYD%5BTIAB%5D%29+OR+%28dihydropyrimidine+dehydrogenase%5BTIAB%5D%29%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D%29%29%29>)

Catalog of Genes and Diseases from OMIM

- DIHYDROPYRIMIDINE DEHYDROGENASE; DPYD (<https://omim.org/entry/612779>)

Gene and Variant Databases

- NCBI Gene (<https://www.ncbi.nlm.nih.gov/gene/1806>)
- ClinVar ([https://www.ncbi.nlm.nih.gov/clinvar?term=DPYD\[gene\]](https://www.ncbi.nlm.nih.gov/clinvar?term=DPYD[gene]))

References

- Al-Sanna A, Van Kuilenburg AB, Atrak TM, Abdul-Jabbar MA, Van Gennip AH. Dihydropyrimidine dehydrogenase deficiency presenting at birth. J Inher Metab Dis. 2005;28(5):793-6. doi: 10.1007/s10545-005-4218-0. Citation on PubMed (

<https://pubmed.ncbi.nlm.nih.gov/16151913>)

- Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routinedihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-relatedsevere toxicities: hype or hope? Clin Colorectal Cancer. 2010 Oct;9(4):224-8.doi: 10.3816/CCC.2010.n.033. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/20920994>)
- Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increasedprevalence of dihydropyrimidine dehydrogenase deficiency in African-Americanscompared with Caucasians. Clin Cancer Res. 2006 Sep 15;12(18):5491-5. doi:10.1158/1078-0432.CCR-06-0747. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/17000684>)
- Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB. Dihydropyrimidinedehydrogenase deficiency in an Indian population. Cancer Chemother Pharmacol.2006 Sep;58(3):396-401. doi: 10.1007/s00280-005-0174-5. Epub 2006 Jan 19. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/16421754>)
- van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinicalaspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem. 2003Jan;40(Pt 1):41-5. doi: 10.1258/000456303321016150. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/12542909>)
- van Kuilenburg AB, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, NowaczykMJ, Maropoulos GD, Hein G, Kalhoff H, Kirk JM, Baaske H, Aukett A, Duley JA, WardKP, Lindqvist Y, van Gennip AH. Novel disease-causing mutations in thedihydropyrimidine dehydrogenase gene interpreted by analysis of thethree-dimensional protein structure. Biochem J. 2002 May 15;364(Pt 1):157-63.doi: 10.1042/bj3640157. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/11988088>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222557/>)
- van Kuilenburg AB, Meijer J, Mul AN, Hennekam RC, Hoovers JM, de Die-SmuldersCE, Weber P, Mori AC, Bierau J, Fowler B, Macke K, Sass JO, Meinsma R, HennermannJB, Miny P, Zoetekouw L, Vijzelaar R, Nicolai J, Ylstra B, Rubio-Gozalbo ME. Analysis of severely affected patients with dihydropyrimidine dehydrogenasedeficiency reveals large intragenic rearrangements of DPYD and a de novointerstitial deletion del(1)(p13.3p21.3). Hum Genet. 2009 Jun;125(5-6):581-90.doi: 10.1007/s00439-009-0653-6. Epub 2009 Mar 19. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/19296131>)
- Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, De Abreu RA, Smeitink JA, Kayserili H, Apak MY, Christensen E, Holopainen I, Pulkki K, Riva D, Botteon G, Holme E, Tulinius M, Kleijer WJ, Beemer FA, Duran M, Niezen-Koning KE, Smit GP, Jakobs C, Smit LM, Van Gennip AH, et al. Genotype andphenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet.1999 Jan;104(1):1-9. doi: 10.1007/pl00008711. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/10071185>)

Genomic Location

The *DPYD* gene is found on chromosome 1 (<https://medlineplus.gov/genetics/chromosome/1/>).

Last updated November 1, 2011